Schizophrenia and Schizoaffective Disorders

Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.

Page 26

Recently published articles about Schizophrenia/Schizoaffective Disorders

Article

Real-World Use of Long-Acting Injectable Antipsychotics

March 23, 2017

Is use of long-acting injectable antipsychotics increasing in patients with schizophrenia? Read this study to find out about current prescription patterns and which patients might benefit most from these...

Vanessa Sanchez-Gistau, Elisabet Vilella, Ana M. Gaviria, et al

Article

Long-Acting Injectable Antipsychotics for Schizophrenia

February 23, 2017

It is crucial that we find ways to support medication adherence for patients with schizophrenia. Long-acting injectable antipsychotic (LAI) medications are an option. In this CME study, the authors...

James McCreath, Essie Larson, Purabi Bharatiya, et al

Original Research

Effects of Herpesviridae and Toxoplasma gondii Infection on Cognition

January 25, 2017

Exposure to infectious agents has been proposed as a risk factor in the development of serious mental illness. How is cognitive functioning affected by these agents? Does exposure to...

Marion Leboyer, Faith B. Dickerson, Stéphane Jamain, et al

Original Research

Functional Recovery After Postpartum Psychosis

January 25, 2017

What is the course of recovery from postpartum psychosis? A group from the Netherlands looked at the degree of psychological distress and level of psychosocial functioning in patients with...

Karin M. Burgerhout, Astrid M. Kamperman, Sabine J. Roza, et al

Letter to the Editor

Aripiprazole and Impulse-Control Disorders

January 12, 2017

The US Food and Drug Administration released a safety announcement regarding aripiprazole and the induction of impulse-control disorders. Read the case of a man with schizophrenia who experienced pathological...

Prashant Tibrewal, Rohan Dhillon, Tarun Bastiampillai, et al

Letter to the Editor

Aripiprazole-Induced Hypersexuality

December 29, 2016

The US Food and Drug Administration issued a warning regarding impulse-control behaviors in patients taking aripiprazole. Here, read about a patient with bipolar disorder who developed hypersexuality following aripiprazole...

Andrea Bulbena-Cabré, Antonio Bulbena